Comparative Pharmacology
Head-to-head clinical analysis: CYCLESSA versus LOW QUEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLESSA versus LOW QUEL.
CYCLESSA vs LOW-QUEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial receptivity.
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
One tablet (0.15 mg desogestrel/0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
10 mg orally twice daily; not to exceed 20 mg/day.
None Documented
None Documented
Desogestrel: 38±13 hours (terminal); ethinyl estradiol: 14±3 hours (terminal). Steady-state reached after 7-10 days.
Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (CrCl 30-50 mL/min).
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); enterohepatic circulation.
Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive